Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Dianthus Therapeutics, Inc. /de/ (MGTA) since 2018 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Dianthus Therapeutics, Inc. /de/. Table 2 shows the detailed insider transactions. This company's CIK number is 1690585.
Total stock buying since 2018: $11,556,230.
Total stock sales since 2018: $7,269,550.
Total stock option exercises since 2018: $321,538.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2023 | 112,924 | $1,451,230 | 3,700,000 | $3,056,000 | 0 | $0 |
| 2021 | 0 | $0 | 49,583 | $333,691 | 0 | $0 |
| 2020 | 1,250,000 | $10,000,000 | 25,294 | $382,896 | 11,294 | $107,180 |
| 2019 | 0 | $0 | 233,406 | $3,496,963 | 22,588 | $214,358 |
| 2018 | 7,000 | $105,000 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2023-09 | 112,924 | $1,451,230 | 0 | $0 | 0 | $0 |
| 2023-02 | 0 | $0 | 3,700,000 | $3,056,000 | 0 | $0 |
| 2021-09 | 0 | $0 | 49,583 | $333,691 | 0 | $0 |
| 2020-06 | 1,250,000 | $10,000,000 | 0 | $0 | 0 | $0 |
| 2020-01 | 0 | $0 | 25,294 | $382,896 | 11,294 | $107,180 |
| 2019-12 | 0 | $0 | 140,501 | $2,132,763 | 22,588 | $214,358 |
| 2019-11 | 0 | $0 | 10,000 | $113,335 | 0 | $0 |
| 2019-10 | 0 | $0 | 5,000 | $50,065 | 0 | $0 |
| 2019-09 | 0 | $0 | 7,500 | $80,530 | 0 | $0 |
| 2019-08 | 0 | $0 | 7,500 | $100,612 | 0 | $0 |
| 2019-07 | 0 | $0 | 7,500 | $108,022 | 0 | $0 |
| 2019-06 | 0 | $0 | 26,915 | $402,806 | 0 | $0 |
| 2019-03 | 0 | $0 | 28,490 | $508,830 | 0 | $0 |
| 2018-06 | 7,000 | $105,000 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-09-29 | Harwin Peter Evan | Buy | 24,670 | 13.63 | 336,252 |
| 2023-09-26 | Harwin Peter Evan | Buy | 30,000 | 13.15 | 394,500 |
| 2023-09-22 | Randhawa Simrat (Chief Medical Officer) | Buy | 2,000 | 13.20 | 26,400 |
| 2023-09-21 | Randhawa Simrat (Chief Medical Officer) | Buy | 2,000 | 13.20 | 26,400 |
| 2023-09-19 | Harwin Peter Evan (Director) | Buy | 30,000 | 13.20 | 396,000 |
| 2023-09-13 | Harwin Peter Evan | Buy | 9,367 | 11.76 | 110,155 |
| 2023-09-12 | Harwin Peter Evan | Buy | 14,887 | 10.85 | 161,523 |
| 2023-02-08 | Trv Gp Iv, Llc (10% Owner) | Sale | 1,500,000 | .82 | 1,230,000 |
| 2023-02-07 | Trv Gp Iv, Llc (10% Owner) | Sale | 2,200,000 | .83 | 1,826,000 |
| 2021-09-16 | Deardorf Caren (Chief Commercial Officer) | Sale | 6,238 | 6.73 | 41,981 |
| 2021-09-16 | Nichols David Wayne (Chief Technical Officer) | Sale | 5,694 | 6.73 | 38,320 |
| 2021-09-16 | Olson Lisa (See Remarks) | Sale | 5,736 | 6.73 | 38,603 |
| 2021-09-16 | Stants Kristen (Chief People Officer) | Sale | 5,736 | 6.73 | 38,603 |
| 2021-09-16 | Mahoney Stephen F. (See Remarks) | Sale | 5,736 | 6.73 | 38,603 |
| 2021-09-16 | Beetham Thomas W. (See Remarks) | Sale | 6,103 | 6.73 | 41,073 |
| 2021-09-16 | Gardner Jason (See Remarks) | Sale | 14,340 | 6.73 | 96,508 |
| 2020-06-29 | Booth Bruce (Director) | Buy | 1,250,000 | 8.00 | 10,000,000 |
| 2020-01-10 | Gardner Jason (See Remarks) | Sale | 11,200 | 15.25 | 170,800 |
| 2020-01-02 | Davis John C. Jr (Chief Medical Officer) | Sale | 11,294 | 15.04 | 169,816 |
| 2020-01-02 | Davis John C. Jr (Chief Medical Officer) | Option Ex | 11,294 | 9.49 | 107,180 |
| 2020-01-02 | Gardner Jason (See Remarks) | Sale | 2,800 | 15.10 | 42,280 |
| 2019-12-24 | Zdraveski Zoran (See Remarks) | Sale | 7,902 | 16.00 | 126,432 |
| 2019-12-24 | Isacson Christina K. (Chief Business Officer) | Sale | 4,463 | 16.01 | 71,452 |
| 2019-12-23 | Gardner Jason (See Remarks) | Sale | 2,897 | 15.10 | 43,753 |
| 2019-12-23 | Zdraveski Zoran (See Remarks) | Sale | 4,181 | 16.03 | 67,021 |
| 2019-12-23 | Isacson Christina K. (Chief Business Officer) | Sale | 9,867 | 16.03 | 158,168 |
| 2019-12-20 | Davis John C. Jr (Chief Medical Officer) | Sale | 919 | 15.00 | 13,785 |
| 2019-12-20 | Davis John C. Jr (Chief Medical Officer) | Option Ex | 919 | 9.49 | 8,721 |
| 2019-12-20 | Gardner Jason (See Remarks) | Sale | 76,711 | 15.16 | 1,162,631 |
| 2019-12-10 | Davis John C. Jr (Chief Medical Officer) | Sale | 17,055 | 15.00 | 255,825 |
| 2019-12-10 | Davis John C. Jr (Chief Medical Officer) | Option Ex | 17,055 | 9.49 | 161,851 |
| 2019-12-10 | Gardner Jason (See Remarks) | Sale | 4,392 | 15.10 | 66,319 |
| 2019-12-09 | Davis John C. Jr (Chief Medical Officer) | Sale | 4,614 | 15.00 | 69,210 |
| 2019-12-09 | Davis John C. Jr (Chief Medical Officer) | Option Ex | 4,614 | 9.49 | 43,786 |
| 2019-12-02 | Cooke Michael P. (Chief Scientific Officer) | Sale | 7,500 | 13.09 | 98,167 |
| 2019-11-20 | Cooke Michael P. (Chief Scientific Officer) | Sale | 5,000 | 12.00 | 60,000 |
| 2019-11-01 | Cooke Michael P. (Chief Scientific Officer) | Sale | 5,000 | 10.67 | 53,335 |
| 2019-10-01 | Cooke Michael P. (Chief Scientific Officer) | Sale | 5,000 | 10.01 | 50,065 |
| 2019-09-19 | Cooke Michael P. (Chief Scientific Officer) | Sale | 1,656 | 12.00 | 19,872 |
| 2019-09-12 | Cooke Michael P. (Chief Scientific Officer) | Sale | 844 | 12.00 | 10,128 |
| 2019-09-03 | Cooke Michael P. (Chief Scientific Officer) | Sale | 5,000 | 10.11 | 50,530 |
| 2019-08-01 | Cooke Michael P. (Chief Scientific Officer) | Sale | 7,500 | 13.41 | 100,612 |
| 2019-07-01 | Cooke Michael P. (Chief Scientific Officer) | Sale | 7,500 | 14.40 | 108,022 |
| 2019-06-21 | Gardner Jason (See Remarks) | Sale | 12,331 | 15.11 | 186,321 |
| 2019-06-21 | Isacson Christina K. (Chief Business Officer) | Sale | 5,415 | 16.07 | 87,019 |
| 2019-06-20 | Gardner Jason (See Remarks) | Sale | 1,669 | 15.10 | 25,201 |
| 2019-06-17 | Cooke Michael P. (Chief Scientific Officer) | Sale | 7,500 | 13.90 | 104,265 |
| 2019-03-20 | Atlas Venture Associates X, Llc (10% Owner) | Sale | 14,245 | 17.86 | 254,415 |
| 2019-03-20 | Booth Bruce (Director) | Sale | 14,245 | 17.86 | 254,415 |
| 2018-06-25 | Gardner Jason (See Remarks) | Buy | 400 | 15.00 | 6,000 |
| 2018-06-25 | Scadden David (Director) | Buy | 6,600 | 15.00 | 99,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of MGTA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Dianthus Therapeutics, Inc. /de/ (symbol MGTA, CIK number 1690585) see the Securities and Exchange Commission (SEC) website.